posted on 2024-03-22, 18:06authored byNoriyasu Haginoya, Masanori Suzuki, Makoto Suzuki, Yutaka Ishigai, Koji Terayama, Akira Kanda, Kazuyuki Sugita
Squalene synthase is one of the most promising pharmaceutical
targets
to treat hyperlipidemia. Inhibition of the squalene synthase causes
a decrease in the hepatic cholesterol concentration. We have already
reported the design and synthesis of highly potent benzhydrol-type
squalene inhibitors. Although these templates showed unique and potent
cyclic active conformations via intramolecular hydrogen bonds, the in vivo cholesterol-lowering efficacy was insufficient.
We attempted to improve their potential as an orally active medicine.
In our medicinal chemistry effort, cyclized 11-membered ring templates
were acquired. The novel series of compounds exhibited potent squalene
synthase inhibitory activity, and one of the derivatives, isomer
A-(1S, 3R)-14i, showed plasma lipid-lowering efficacy
in hamster and marmoset repeated-dose studies. Our findings provide
valuable insights into the design and development of novel and unique
11-membered ring-type highly potent squalene synthase inhibitors.